Amid rising healthcare costs and shrinking government coverage, two major patient assistance charities have announced a strategic merger they say will help ramp up aid.  | The Patient Advocate ...

Anna Sutton was shocked when she received a letter from her husband’s job-based health plan stating that Humira, an expensive drug used to treat her daughter’s juvenile arthritis, was now on a long ...

The Patient Advocate Foundation and the Patient Access Network Foundation merged March 3, creating the nation’s largest portfolio of financial assistance programs for low- and middle-income patients.

In the rapidly evolving landscape of healthcare, Pharma Patient Assistance Programs (PAP) have been a lifeline for many patients seeking access to essential medications. These programs aim to help ...

Please provide your email address to receive an email when new articles are posted on . The programs are designed to provide anti-VEGF treatment for patients who are uninsured or underinsured.

To ease the financial burdens patients struggle with because of high out-of-pocket costs, Northwell Health is enhancing its financial assistance programs. The initiative includes the introduction of a ...

On January 15, 2025, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 25-01, a favorable opinion analyzing a pharmaceutical manufacturer’s ...

In a highly watched case relating to the ability of pharmaceutical manufacturers to support patient copay assistance, the Southern District of New York recently denied Pfizer's request for a ...

Limited evidence from a literature review suggests that co-pay assistance was associated with improved treatment persistence/adherence across various diseases, with indirect evidence suggesting ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The emergence of Lilly’s bundling strategy for Zepbound and Taltz reflects the unregulated state of patient assistance programs in the commercial market and the need for Congressional intervention.